Tests LY4052031 in adults with advanced solid tumors, including urothelial cancer
Tests the drug LY4052031 in adults with advanced or spreading solid tumors, including urothelial cancer.
Plain-language title generated from the registry record
Registry title: A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Key facts
- Where
- Chūōku, Kashiwa, Chiba, Kōtō City, and Nagoya, JapanSee the 4 sites
- Phase
- Phase 1
Where in Japan
- National Cancer Center HospitalChūōku, JapanTaking people
- National Cancer Center Hospital EastKashiwa, Chiba, JapanTaking people
- The Cancer Institute Hospital of JFCRKōtō City, JapanTaking people
- Aichi Cancer Center HospitalNagoya, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06465069EU 2024-512927-36-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.Read full original descriptionShow less
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Inclusion: Have one of the following solid tumor cancers:; Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer; Cohort A2/B/D: urothelial carcinoma; Cohort C: triple negative breast cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, HNSCC (head and neck squamous cell carcinoma), esophageal cancer, pancreatic cancer, or prostate cancer; Prior Systemic Therapy Criteria:; Cohort A1/C: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies; Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies; Cohort D: Treatment-naive for locally advanced or metastatic urothelial cancer; Prior enfortumab vedotin specific requirements:; Cohorts A1/A2/C/D: prior treatment with enfortumab vedotin is allowed, but not required; Cohort B1: individual must be enfortumab vedotin naive in the advanced/metastatic setting; Cohort B2: individual must have received enfortumab vedotin in the metastatic/advanced setting; Measurability of disease; Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1); Measurable disease is required as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for all Cohorts. Cohort A1 may permit non-measurable disease as defined by RECIST v1.1; Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations.
Exclusion: Any serious unresolved toxicities from prior therapy; Individual with uncontrolled diabetes; Individual with evidence of corneal keratopathy or keratitis, and history of corneal transplant; Significant cardiovascular disease; Recent thromboembolic event and/or clinically significant bleeding disorder; History of pneumonitis/interstitial lung disease; History of Grade ≥3 skin toxicity associated with enfortumab vedotin that required treatment discontinuation; Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms; Individual with known or suspected uncontrolled CNS metastases; Individual with uncontrolled hypercalcemia; Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention.